

Express Mail Label No.: ED 798634993 US Attorney Docket No.: 100869-1P US



NTD

GIPS ______ Date of mailing AWI

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT
NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY
(PCT Rule 71.1)

Italiang
Italyear)
07.03.2005

Applicant's or agent's file reference 100869-1 WO CHECK (day/month/year)

CODE

IMPORTANT NOTIFICATION

International application No. PCT/GB2004/001132

ASTRAZENECA

SUEDE

S-151 85 Södertälje

Global Intellectual Property

International filing date (day/month/year) 16.03.2004

ANKOM 16 MAR 2005

DATE

Priority date (day/month/year)

20.03.2003

Applicant

ASTRAZENECA AB et al.

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:

<u>@</u>)

European Patent Office - P.B. 5818 Patentiaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016 Authorized Officer

Cardenas, C

Tel. +31 70 340-3370



ATENT	COOPERATION	TREAT

ANKOM 16 MAR 2005

DATE

CODE

NTD

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Telly)

(PCT Article 36 and Rule 70)

Applic	cant's or agent's file i	eference	FOR FURTHER AC	TION	See Form PCTAPEA/416	
100869-1 WO			,1014	See Form PCI//PEA416		
International application No. International filing date (d		ay/month/year)	Priority date (day/month/year	,		
PCT/GB2004/001132 16.03.2004				20.03.2003		
Intern	ational Patent Class	ification (IPC) or na	ational classification and IP		•	
C07	D413/14, C07F9/	6558, A 61K31	422, A61K31 <i>6</i> 75, A61	P31/04		
		•				ļ
Apolio	cant					
Applicant ASTRAZENECA AB et al.					}	
1.	Authority under A	rticle 35 and trar	nsmitted to the applicant	according to Article 36	s International Preliminary E i.	xamining
2.	This REPORT co	ensists of a total of	of 6 sheets, including th	s cover sheet.		}
3.	• ' '	•	y ANNEXES, comprising			1
			o the International Burea			
	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				07 of the	
	☐ sheet	s which supersed	de earlier sheets, but wh	ich this Authority consi	iders contain an amendmen	t that goes
	be <u>y</u> ar Suppl	nd the disclosure lemental Box.	in the international appl	ication as filed, as indic	cated in item 4 of Box No. I	and the
	sequence	listing and/or tak	oles related thereto, in co	mputer readable form	or of electronic carrier(s)), only, as indicated in the Su	containing a pplemental
	Box Relat	ing to Sequence	Listing (see Section 802	2 of the Administrative	Instructions).	
4.	This report conta	ins indications re	elating to the following ite	ems:		
	Box No. I	Basis of the opi	nion			
	☐ Box No. II	Priority				
	Box No. ill	Non-establishm	ent of opinion with regar	rd to novelty, inventive	step and industrial applicab	ility
	Box No. IV	Lack of unity of				
	☑ Box No. V	Reasoned state applicability; cit	ement under Article 35(2 ations and explanations) with regard to novelty supporting such stater	, inventive step or industria nent	
	Box No. VI	Certain docume	ents cited		•	
	☐ Box No. VII		in the international appl		•	
	☐ Box No. VIII	Certain observa	ations on the internation	al application	_	
Date	of submission of the	demand		Date of completion of th	is report	
22.09.2004		07.03.2005				
preliminary examining authority:			Authorized Officer		J. E.	
European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas			Allard, M			
) 340 - 2040 Tx: 31 0 340 - 3016	1 651 epo ni	Telephone No. +31 70	340-2002	
				. Sicprions 140. 701 70		- Organ assure

10/551324

JC09 Rec'c T/PTO 23 SEP 2005.



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/001132

_	Box No. I	Basis of the report
	With regard	d to the language , this report is based on the international application in the language in which it was sotherwise indicated under this item.
	which	eport is based on translations from the original language into the following language , is the language of a translation furnished for the purposes of:
	lug 🛘	ernational search (under Rules 12.3 and 23.1(b)) Dication of the international application (under Rule 12.4) Pernational preliminary examination (under Rules 55.2 and/or 55.3)
2.	have been	d to the elements* of the international application, this report is based on (replacement sheets which furnished to the receiving Office in response to an invitation under Article 14 are referred to in this originally filed" and are not annexed to this report):
	Description	n, Pages
	1-58	as originally filed
	Claims, Nu	mbers
	1-12	as originally filed
	□ a seq	uence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3.		mendments have resulted in the cancellation of:
		e description, pages e claims, Nos.
		e drawings, sheets/figs e sequence listing <i>(specify)</i> :
		y table(s) related to sequence listing (specify):
4.	had not be	eport has been established as if (some of) the amendments annexed to this report and listed below een made, since they have been considered to go beyond the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)).
		e description, pages e daims, Nos.
	☐ the	e drawings, sheets/figs
		e sequence listing (specify): y table(s) related to sequence listing (specify):
		to a serious and a serious shorts may be marked "supergoded "



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/001132

		No. III Non-establishment o dicability	f opi	nion with regard to novelty, inventive step and industrial		
1.	The obv	ne questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- povious), or to be industrially applicable have not been examined in respect of:				
		the entire international application,				
	⊠	claims Nos. 7 (in whole), 8, 9-12 (in part)				
		because:				
	⊠	the said international application, or the said claims Nos. 8 relate to the following subject matter which does not require an international preliminary examination (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
	×	no international search report has been established for the said claims Nos. 7 (in whole), 9-12 (in part)				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
		the tables related to the nucleo not comply with the technical re	tide a equir	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.		
		See separate sheet for further	detei	is an artist of the second of		
	ب	See Separate Sheet for Intilier	a-cia:	···		



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/001132

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-6, 8-12

No: Claims

_

Inventive step (IS)

Yes: Claims

No: Claims

s 1-6, 8-12

Industrial applicability (IA)

Yes: Claims

1-6, 9-12

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VI Certain documents cited

 Certain published documents (Rule 70.10) and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

International application No.

PCT/GB2004/001132

Reference is made to the following documents:

D1: WO 01/81350 A (ASTRAZENECA AB ET AL) 1 November 2001 (2001-11-01)

D2: LEE S C ET AL: "Carbon-carbon linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria" BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 9, no. 12, December 2001 (2001-12), pages 3243-3253, XP002283682

D3: PHILILIPS O A ET AL: "Synthesis and antibacterial activity of 5-substituted oxazolidinones" BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 11, no. 1, 2 January 2003 (2003-01-02), pages 35-41, XP002283683

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 8 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

The term "pro-drug" used in claims 7-12 is a functional term, which in the present case is so unclear (Article 6 PCT), even in the light of the description (page 11, line 16, to page 12, line 3), that a meaningful international search with regard to this term is impossible. Consequently, the subject-matter of claim 7 in the whole, and further of claims 8-12 insofar it relates to a "pro-drug", which has not been searched, shall not be the subject of the present opinion, see Rule 66.1 (e) PCT.

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Novelty (Article 33(2) PCT)

The available prior art does not disclose oxazolidinones having the combination of N-HET and T substituents as recited in claim 1 of the present application: the subject-



International application No.

PCT/GB2004/001132

matter of claims 1-6 and 8-12 is therefore novel.

Inventive step (Article 33(3) PCT)

D1, which is considered to represent the closest prior art, describes amongst others antimicrobial 2-oxazolidinones substituted in position 5 by a N-azolylmethyl residue, and substituted in position 3 by a (hetero)aryl radical, itself substituted by a T group, see claims 1 and 12 of D1. The group T may be amongst others an unsaturated 5-membered heteroaryl linked through a carbon atom, like a triazole, pyrazole, isoxazole or isothiazole, see D1, page 8, lines 24-27, and page 27, lines 15-20.

In the light of the teachings of D1, the problem underlying and solved by the present application can be seen in the provision of further antibacterial oxazolidinones.

The solution to this problem proposed in the present application is merely the selection of a combination of meanings of the substituents in position 3 and 5 of the oxazolidinone ring, combination already suggested, but not specifically disclosed, in D1. Such selection does not involve an inventive step in the absence of substantiated surprising resulting effects or properties.

It is moreover noted that such combination is also suggested by the combined teachings of D2 and D3.

The subject-matter of claims 1-6 and 8-12 lacks therefore an inventive step.

Industrial applicability (Article 33(4) PCT)

The compounds, compositions and processes of claims 1-6 and 9-12 can be applied in the pharmaceutical industry.